For the quarter ending 2026-03-31, BEIGF made $1,513,438K in revenue. $227,357K in net income. Net profit margin of 15.02%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues | 1,513,438 | 1,482,614* | 1,412,284 | 1,315,300 |
| Cost of sales - product | 167,215 | 126,866* | 196,510 | 164,606 |
| Gross profit | 1,346,223 | 1,355,748 | 1,215,774 | 1,150,694 |
| Research and development | 541,224 | 615,423 | 523,662 | 524,896 |
| Selling, general and administrative | 555,097 | 555,290 | 528,998 | 537,913 |
| Total operating expenses | 1,096,321 | 1,170,713 | 1,052,660 | 1,062,809 |
| Income from operations | 249,902 | 185,035 | 163,114 | 87,885 |
| Interest income | 27,664 | 14,456* | - | - |
| Interest income, net | - | - | 3,029 | 3,497 |
| Interest expense | 32,887 | 14,559* | - | - |
| Other income, net | 14,536 | -35,691 | -18,979 | 8,167 |
| Income before income taxes | 259,215 | 149,241 | 147,164 | 99,549 |
| Income tax expense | 31,858 | 82,739 | 22,323 | 5,229 |
| Net income | 227,357 | 66,502 | 124,841 | 94,320 |
| Basic EPS | 0.16 | 0.046 | 0.09 | 0.07 |
| Diluted EPS | 0.15 | 0.044 | 0.08 | 0.06 |
| Basic Average Shares | 1,442,451,870 | 1,440,193,489 | 1,432,801,699 | 1,408,166,754 |
| Diluted Average Shares | 1,505,027,338 | 1,502,038,658 | 1,488,750,354 | 1,463,277,401 |
BeOne Medicines Ltd. (BEIGF)
BeOne Medicines Ltd. (BEIGF)